The US National Institutes of Health (NIH) has initiated dosing in a new Phase I clinical trial of Moderna’s investigational vaccine candidate, mRNA-1273.351, in adult subjects.
Moderna has shipped doses of a variant-specific vaccine candidate against the COVID-19 variant first discovered in South Africa, otherwise known as B.1.351, to the US National Institutes of Health (NIH) for clinical study.